Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 Apr 23. doi: 10.1038/s41591-018-0014-x. [Epub ahead of print] Review.

PMID:
29686425
2.

Secretory IgM exacerbates tumor progression by inducing accumulations of MDSCs in mice.

Tang CH, Chang S, Hashimoto A, Chen YJ, Kang CW, Mato AR, Del Valle JR, Gabrilovich D, Hu CC.

Cancer Immunol Res. 2018 Apr 12. pii: canimm.0582.2017. doi: 10.1158/2326-6066.CIR-17-0582. [Epub ahead of print]

PMID:
29650518
3.

CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.

Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI, Rustgi AK.

JCI Insight. 2018 Mar 22;3(6). pii: 97022. doi: 10.1172/jci.insight.97022. [Epub ahead of print]

4.

Plasticity of myeloid-derived suppressor cells in cancer.

Tcyganov E, Mastio J, Chen E, Gabrilovich DI.

Curr Opin Immunol. 2018 Mar 13;51:76-82. doi: 10.1016/j.coi.2018.03.009. [Epub ahead of print] Review.

PMID:
29547768
5.

Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, Fedele C, Liu Q, Tang HY, Kossenkov AV, Kelly WK, Wang K, Kean RB, Weinreb PH, Yu L, Dutta A, Fortina P, Ertel A, Stanczak M, Forsberg F, Gabrilovich DI, Speicher DW, Altieri DC, Languino LR.

Matrix Biol. 2018 Mar 9. pii: S0945-053X(18)30081-7. doi: 10.1016/j.matbio.2018.03.009. [Epub ahead of print]

PMID:
29530483
6.

Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization.

Tang CH, Chang S, Paton AW, Paton JC, Gabrilovich DI, Ploegh HL, Del Valle JR, Hu CC.

J Cell Biol. 2018 Mar 6. pii: jcb.201709137. doi: 10.1083/jcb.201709137. [Epub ahead of print]

PMID:
29511123
7.

Myeloid-derived suppressor cells coming of age.

Veglia F, Perego M, Gabrilovich D.

Nat Immunol. 2018 Feb;19(2):108-119. doi: 10.1038/s41590-017-0022-x. Epub 2018 Jan 18. Review.

PMID:
29348500
8.

Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation.

He YM, Li X, Perego M, Nefedova Y, Kossenkov AV, Jensen EA, Kagan V, Liu YF, Fu SY, Ye QJ, Zhou YH, Wei L, Gabrilovich DI, Zhou J.

Nat Med. 2018 Feb;24(2):224-231. doi: 10.1038/nm.4467. Epub 2018 Jan 15.

PMID:
29334374
9.

Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.

Zhou J, Nefedova Y, Lei A, Gabrilovich D.

Semin Immunol. 2018 Feb;35:19-28. doi: 10.1016/j.smim.2017.12.004. Epub 2017 Dec 15. Review.

PMID:
29254756
10.

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.

Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, Hashimoto A, Kapralov A, Amoscato A, Angelini R, Patel S, Alicea-Torres K, Weiner D, Murphy ME, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI.

Nat Commun. 2017 Dec 14;8(1):2122. doi: 10.1038/s41467-017-02186-9.

11.

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.

12.

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI.

Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

PMID:
29136508
13.

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.

Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

14.

Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer.

Caino MC, Seo JH, Wang Y, Rivadeneira DB, Gabrilovich DI, Kim ET, Weeraratna AT, Languino LR, Altieri DC.

J Clin Invest. 2017 Oct 2;127(10):3755-3769. doi: 10.1172/JCI93172. Epub 2017 Sep 11.

15.

"Only a Life Lived for Others Is Worth Living": Redox Signaling by Oxygenated Phospholipids in Cell Fate Decisions.

Tyurina YY, Shrivastava I, Tyurin VA, Mao G, Dar HH, Watkins S, Epperly M, Bahar I, Shvedova AA, Pitt B, Wenzel SE, Mallampalli RK, Sadovsky Y, Gabrilovich D, Greenberger JS, Bayır H, Kagan VE.

Antioxid Redox Signal. 2017 Oct 16. doi: 10.1089/ars.2017.7124. [Epub ahead of print]

PMID:
28835115
16.

Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R.

Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. doi: 10.1158/1078-0432.CCR-17-0741. Epub 2017 Jul 11.

PMID:
28698201
17.

Editorial overview: Many shades of grey: how immune response is regulated by tumors.

Gabrilovich D, Ferris RL.

Curr Opin Immunol. 2017 Apr;45:ix-xi. doi: 10.1016/j.coi.2017.05.003. No abstract available.

18.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.

Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.

19.

Dendritic cells in cancer: the role revisited.

Veglia F, Gabrilovich DI.

Curr Opin Immunol. 2017 Apr;45:43-51. doi: 10.1016/j.coi.2017.01.002. Epub 2017 Feb 10. Review.

20.

Myeloid-Derived Suppressor Cells.

Gabrilovich DI.

Cancer Immunol Res. 2017 Jan;5(1):3-8. doi: 10.1158/2326-6066.CIR-16-0297. Review.

21.

A neuronal network of mitochondrial dynamics regulates metastasis.

Caino MC, Seo JH, Aguinaldo A, Wait E, Bryant KG, Kossenkov AV, Hayden JE, Vaira V, Morotti A, Ferrero S, Bosari S, Gabrilovich DI, Languino LR, Cohen AR, Altieri DC.

Nat Commun. 2016 Dec 19;7:13730. doi: 10.1038/ncomms13730.

22.

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.

Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI.

Clin Cancer Res. 2017 Jun 15;23(12):2942-2950. doi: 10.1158/1078-0432.CCR-16-1784. Epub 2016 Dec 13.

PMID:
27965309
23.

β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation.

Sayeed A, Lu H, Liu Q, Deming D 2nd, Duffy A, McCue P, Dicker AP, Davis RJ, Gabrilovich D, Rodeck U, Altieri DC, Languino LR.

Oncotarget. 2016 Aug 16;7(33):52618-52630. doi: 10.18632/oncotarget.10522.

24.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

25.

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.

Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, Denstman F, Xu X, Altieri DC, Du H, Yan C, Gabrilovich DI.

Immunity. 2016 Feb 16;44(2):303-15. doi: 10.1016/j.immuni.2016.01.014.

26.

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Kumar V, Patel S, Tcyganov E, Gabrilovich DI.

Trends Immunol. 2016 Mar;37(3):208-220. doi: 10.1016/j.it.2016.01.004. Epub 2016 Feb 6. Review.

27.

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, Gabrilovich DI, Nefedova Y.

Cancer Lett. 2016 Feb 1;371(1):117-24. doi: 10.1016/j.canlet.2015.10.040. Epub 2015 Nov 27.

28.

Transcriptional regulation of myeloid-derived suppressor cells.

Condamine T, Mastio J, Gabrilovich DI.

J Leukoc Biol. 2015 Dec;98(6):913-22. doi: 10.1189/jlb.4RI0515-204R. Epub 2015 Sep 3. Review.

29.

ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.

Gabrilovich D, Nefedova Y.

Cancer Cell. 2015 Aug 10;28(2):147-9. doi: 10.1016/j.ccell.2015.07.007.

30.

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.

31.

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Marvel D, Gabrilovich DI.

J Clin Invest. 2015 Sep;125(9):3356-64. doi: 10.1172/JCI80005. Epub 2015 Jul 13. Review.

32.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

33.

Fatal attraction: How macrophages participate in tumor metastases.

Gabrilovich D.

J Exp Med. 2015 Jun 29;212(7):976. doi: 10.1084/jem.2127insight1. No abstract available.

34.

Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C.

J Immunother Cancer. 2015 May 19;3:20. doi: 10.1186/s40425-015-0065-1. eCollection 2015.

35.

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.

Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L, Condamine T, Seykora J, Knight SC, Malietzis G, Lee GH, Moorghen M, Lenox B, Luetteke N, Celis E, Gabrilovich D.

J Exp Med. 2015 Mar 9;212(3):351-67. doi: 10.1084/jem.20140835. Epub 2015 Feb 9.

36.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

37.

Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate?

Gabrilovich DI.

J Leukoc Biol. 2014 Nov;96(5):671-4. doi: 10.1189/jlb.4CE0514-271R. No abstract available.

38.

Regulation of tumor metastasis by myeloid-derived suppressor cells.

Condamine T, Ramachandran I, Youn JI, Gabrilovich DI.

Annu Rev Med. 2015;66:97-110. doi: 10.1146/annurev-med-051013-052304. Epub 2014 Oct 9. Review.

39.

Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?

Condamine T, Gabrilovich DI.

Immunity. 2014 Sep 18;41(3):341-342. doi: 10.1016/j.immuni.2014.08.016.

40.

Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.

Kumar V, Gabrilovich DI.

Immunology. 2014 Dec;143(4):512-9. doi: 10.1111/imm.12380. Review.

41.

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J.

Mol Immunol. 2015 Feb;63(2):579-85. doi: 10.1016/j.molimm.2014.08.002. Epub 2014 Aug 23.

42.

Molecular speciation and dynamics of oxidized triacylglycerols in lipid droplets: Mass spectrometry and coarse-grained simulations.

Mohammadyani D, Tyurin VA, O'Brien M, Sadovsky Y, Gabrilovich DI, Klein-Seetharaman J, Kagan VE.

Free Radic Biol Med. 2014 Nov;76:53-60. doi: 10.1016/j.freeradbiomed.2014.07.042. Epub 2014 Aug 10.

43.

COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse.

Yang Q, Shi M, Shen Y, Cao Y, Zuo S, Zuo C, Zhang H, Gabrilovich DI, Yu Y, Zhou J.

Blood. 2014 Sep 4;124(10):1610-21. doi: 10.1182/blood-2014-03-559658. Epub 2014 Jul 16.

44.

Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice.

Kim S, Ramakrishnan R, Lavilla-Alonso S, Chinnaiyan P, Rao N, Fowler E, Heine J, Gabrilovich DI.

Cancer Immunol Immunother. 2014 Oct;63(10):1009-21. doi: 10.1007/s00262-014-1573-4. Epub 2014 Jun 19.

45.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

46.

Myeloid-derived suppressor cells in the development of lung cancer.

Ortiz ML, Lu L, Ramachandran I, Gabrilovich DI.

Cancer Immunol Res. 2014 Jan;2(1):50-8. doi: 10.1158/2326-6066.CIR-13-0129. Epub 2013 Oct 18.

47.

Dendritic cells transfected with adenoviral vectors as vaccines.

Senesac J, Gabrilovich D, Pirruccello S, Talmadge JE.

Methods Mol Biol. 2014;1139:97-118. doi: 10.1007/978-1-4939-0345-0_10.

PMID:
24619674
48.

Oxidized lipids block antigen cross-presentation by dendritic cells in cancer.

Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Zhang LM, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI.

J Immunol. 2014 Mar 15;192(6):2920-31. doi: 10.4049/jimmunol.1302801. Epub 2014 Feb 19. Erratum in: J Immunol. 2014 May 15;192(10):4935. Tuyrin, Vladimir A [corrected to Tyurin, Vladimir A]; Cao, Wei [removed].

49.

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP.

Sci Signal. 2014 Feb 18;7(313):ra16. doi: 10.1126/scisignal.2004656.

50.

Effects of notch signaling on regulation of myeloid cell differentiation in cancer.

Cheng P, Kumar V, Liu H, Youn JI, Fishman M, Sherman S, Gabrilovich D.

Cancer Res. 2014 Jan 1;74(1):141-52. doi: 10.1158/0008-5472.CAN-13-1686. Epub 2013 Nov 12.

Supplemental Content

Loading ...
Support Center